Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Capital Expenditures of $178000.0 for Q1 2026, up 45.9% year-over-year from $122000.0 in Q1 2025, and up 23.61% quarter-over-quarter from $144000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Capital Expenditures for 15 consecutive years, with $178000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 45.9% year-over-year to $178000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 43.52% YoY), while the FY2025 annual figure was $1.2 million, down 48.6% from the prior year.
- Capital Expenditures rose to $178000.0 in Q1 2026 per GYRE's latest filing, from $144000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.5 million in Q2 2023 and bottomed at -$65000.0 in Q4 2024.
- Historically, Capital Expenditures has averaged $938461.5 across 4 years, with a median of $668000.0 in 2025.
- Annual changes were most pronounced in 2024 — Capital Expenditures sank 102.8% — and 2025, when it surged 321.54%.
- Gyre Therapeutics' Capital Expenditures stood at $2.3 million in 2023, then tumbled by 102.8% to -$65000.0 in 2024, then soared by 321.54% to $144000.0 in 2025, then grew by 23.61% to $178000.0 in 2026.
- Business Quant data shows GYRE's Capital Expenditures at $178000.0 in Q1 2026, $144000.0 in Q4 2025, and $668000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | 262,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 262,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 335,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 231,000.00 |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 2.48 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Sep 30, 2021 | 492,000.00 |
| Sep 30, 2020 | 195,000.00 |
| Jun 30, 2020 | 16,000.00 |
| Mar 31, 2020 | 17,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Sep 30, 2019 | 1,000.00 |